Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 23, 2026

Elon Musk's Terafab is here: What it is, and why it's important for Tesla and SpaceX

View original at finance.yahoo.com
Elon Musk's Terafab is here: What it is, and why it's important for Tesla and SpaceX Over the weekend in Austin, Texas, Tesla (TSLA) and SpaceX (SPAX.PVT) CEO Elon Musk unveiled what might be his grandest overarching vision for where he sees his companies headed…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Terafab is the most epic chip-building exercise in history by far

    60% confidence

  • Current AI compute output is roughly 20 gigawatts per year and the rest of the world's output is about 2% of what his companies need

    60% confidence

  • Chipmakers' expansion rate is much less than what Musk's companies would like

    60% confidence

  • We either build the Terafab or we don't have the chips, and we need the chips, so we build the Terafab

    60% confidence

  • Goal is to produce more than a terawatt — 1 trillion watts — of AI computing power per year, with most of that capacity ultimately destined for space

    60% confidence

  • Giga Texas alone is expected to have capacity for 10 million humanoid robots per year, which would require 20 million chips — approximately six times Tesla's current chip demand for its entire auto business

    60% confidence

  • Chipmakers like TSMC and Samsung aren't making chips fast enough for his companies' AI and robotics needs

    60% confidence

Data points we hold from this source

Elon Musk · ai compute output worldwide20 gigawatts_per_year
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Elon Musk's Terafab is here: What it is, and why it's important for Tesla and SpaceX — Source | Via News | ViaNews Market